These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 30004659)
1. [Immune Effects and Mechanisms of HIV-specific Antibodies Against Viral Infection]. Su B; Li L; Mou D; Moog C; Wu H; Zhang T Bing Du Xue Bao; 2016 Nov; 32(6):830-8. PubMed ID: 30004659 [TBL] [Abstract][Full Text] [Related]
2. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431 [TBL] [Abstract][Full Text] [Related]
3. Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies. Parsons MS; Chung AW; Kent SJ Retrovirology; 2018 Aug; 15(1):58. PubMed ID: 30134945 [TBL] [Abstract][Full Text] [Related]
4. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs. Li H; Zony C; Chen P; Chen BK J Virol; 2017 May; 91(9):. PubMed ID: 28148796 [TBL] [Abstract][Full Text] [Related]
5. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques. Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476 [TBL] [Abstract][Full Text] [Related]
6. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. Richardson SI; Chung AW; Natarajan H; Mabvakure B; Mkhize NN; Garrett N; Abdool Karim S; Moore PL; Ackerman ME; Alter G; Morris L PLoS Pathog; 2018 Apr; 14(4):e1006987. PubMed ID: 29630668 [TBL] [Abstract][Full Text] [Related]
8. Vaccinal effect of HIV-1 antibody therapy. Naranjo-Gomez M; Pelegrin M Curr Opin HIV AIDS; 2019 Jul; 14(4):325-333. PubMed ID: 30973419 [TBL] [Abstract][Full Text] [Related]
9. B-cell abnormalities and impact on antibody response in HIV infection. Noto A; Pantaleo G Curr Opin HIV AIDS; 2017 May; 12(3):203-208. PubMed ID: 28422784 [TBL] [Abstract][Full Text] [Related]
10. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies. Zhang Z; Li S; Gu Y; Xia N Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733 [TBL] [Abstract][Full Text] [Related]
11. [Anti-HIV antibodies: multiple antiviral activities]. Peressin M; Holl V; Moog C Med Sci (Paris); 2014 Jan; 30(1):69-75. PubMed ID: 24472462 [TBL] [Abstract][Full Text] [Related]
12. Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection. Su B; Peressin M; Ducloy C; Penichon J; Mayr LM; Laumond G; Schmidt S; Decoville T; Moog C AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1187-91. PubMed ID: 26252799 [TBL] [Abstract][Full Text] [Related]
13. Prospects for a globally effective HIV-1 vaccine. Excler JL; Robb ML; Kim JH Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921 [TBL] [Abstract][Full Text] [Related]
14. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Freund NT; Wang H; Scharf L; Nogueira L; Horwitz JA; Bar-On Y; Golijanin J; Sievers SA; Sok D; Cai H; Cesar Lorenzi JC; Halper-Stromberg A; Toth I; Piechocka-Trocha A; Gristick HB; van Gils MJ; Sanders RW; Wang LX; Seaman MS; Burton DR; Gazumyan A; Walker BD; West AP; Bjorkman PJ; Nussenzweig MC Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100831 [TBL] [Abstract][Full Text] [Related]
15. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. Martinez DR; Vandergrift N; Douglas AO; McGuire E; Bainbridge J; Nicely NI; Montefiori DC; Tomaras GD; Fouda GG; Permar SR J Virol; 2017 May; 91(9):. PubMed ID: 28202762 [TBL] [Abstract][Full Text] [Related]
16. The antibody response in HIV-1-infected donors. Richardson SI; Moore PL Curr Opin HIV AIDS; 2019 Jul; 14(4):233-239. PubMed ID: 31033730 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials. Moldt B; Parvangada A; Martin R; Pace C; Balakrishnan M; Thomsen ND; E Collins S; Kuster H; Braun DL; Günthard HF; Geleziunas R; Callebaut C J Acquir Immune Defic Syndr; 2021 Sep; 88(1):61-69. PubMed ID: 34397744 [TBL] [Abstract][Full Text] [Related]
18. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies. Ahmed Y; Tian M; Gao Y AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278 [TBL] [Abstract][Full Text] [Related]
19. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259 [TBL] [Abstract][Full Text] [Related]
20. Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity. Lorin V; Malbec M; Eden C; Bruel T; Porrot F; Seaman MS; Schwartz O; Mouquet H Mucosal Immunol; 2017 May; 10(3):814-826. PubMed ID: 27966557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]